HomeCompareSGTSY vs PFE

SGTSY vs PFE: Dividend Comparison 2026

SGTSY yields 200.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGTSY wins by $119.31M in total portfolio value
10 years
SGTSY
SGTSY
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full SGTSY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SGTSY vs PFE

📍 SGTSY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGTSYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGTSY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGTSY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGTSY
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SGTSY beats the other by $51,127,361.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGTSY + PFE for your $10,000?

SGTSY: 50%PFE: 50%
100% PFE50/50100% SGTSY
Portfolio after 10yr
$59.71M
Annual income
$30,101,177.50/yr
Blended yield
50.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SGTSY
No analyst data
Altman Z
-1.8
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGTSY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGTSYPFE
Forward yield200.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$119.36M$49.6K
Annual income after 10y$60,176,096.29$26,258.71
Total dividends collected$112.49M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGTSY vs PFE ($10,000, DRIP)

YearSGTSY PortfolioSGTSY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$30,700$20,000.00$9,153$693.39+$21.5KSGTSY
2$90,232$57,383.18$8,593$849.25+$81.6KSGTSY
3$254,173$157,624.56$8,336$1,066.78+$245.8KSGTSY
4$686,927$414,961.74$8,437$1,384.80+$678.5KSGTSY
5$1,783,118$1,048,106.39$9,013$1,875.40+$1.77MSGTSY
6$4,450,613$2,542,677.12$10,306$2,680.72+$4.44MSGTSY
7$10,693,420$5,931,263.38$12,820$4,101.38+$10.68MSGTSY
8$24,760,608$13,318,648.86$17,673$6,826.70+$24.74MSGTSY
9$55,315,649$28,821,798.66$27,543$12,591.86+$55.29MSGTSY
10$119,363,841$60,176,096.29$49,560$26,258.71+$119.31MSGTSY

SGTSY vs PFE: Complete Analysis 2026

SGTSYStock

Singulus Technologies AG, together with its subsidiaries, develops, builds, and sells machinery in the areas of vacuum deposition, surface engineering, wet chemical, and thermal processing technologies worldwide. The company operates through three segments: Solar, Life Science, and Semiconductor. The Solar segment develops production solutions to manufacture solar cell concepts, including heterojunction, interdigitated back contact, and tunnel oxide passivated contacts for crystalline and thin-film solar cells. The Life Science segment offers product solutions for medical technology, decorative coating, and data storage; and develops an integrated product line DECOLINE II, inline vacuum cathode sputtering machine POLYCOATER, and MEDLINE for application in medical technologies. This segment also provides data storage machines for the production of optical disc formats comprising of CD, DVD, dual layer Blu-ray, and Ultra HD Blu-ray discs. The Semiconductor segment supplies special purpose machines and machine platforms, such as TIMARIS and ROTARIS for use in magneto resistive random access memory, sensors, power controllers, and microelectromechanical systems. Singulus Technologies AG was founded in 1995 and is headquartered in Kahl am Main, Germany.

Full SGTSY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SGTSY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGTSY vs SCHDSGTSY vs JEPISGTSY vs OSGTSY vs KOSGTSY vs MAINSGTSY vs JNJSGTSY vs MRKSGTSY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.